Display options
Cite
Liu H, Kong QF, Li J, et al. A meta-analysis for comparison of partial nephrectomy . Transl Androl Urol. 2021;10(3):1170-1178doi: 10.21037/tau-20-1262.
Liu, H., Kong, Q. F., Li, J., Wu, Y. Q., Pan, K. H., Xu, B., Wang, Y. L., & Chen, M. (2021). A meta-analysis for comparison of partial nephrectomy . Translational andrology and urology, 10(3), 1170-1178. https://doi.org/10.21037/tau-20-1262
Liu, Hui, et al. "A meta-analysis for comparison of partial nephrectomy ." Translational andrology and urology vol. 10,3 (2021): 1170-1178. doi: https://doi.org/10.21037/tau-20-1262
Liu H, Kong QF, Li J, Wu YQ, Pan KH, Xu B, Wang YL, Chen M. A meta-analysis for comparison of partial nephrectomy . Transl Androl Urol. 2021 Mar;10(3):1170-1178. doi: 10.21037/tau-20-1262. PMID: 33850752; PMCID: PMC8039616.
Copy Download .nbib Format: NLM
Share it on

Transl Androl Urol. 2021 Mar;10(3):1170-1178. doi: 10.21037/tau-20-1262.

A meta-analysis for comparison of partial nephrectomy .

Translational andrology and urology

Hui Liu, Qing-Fang Kong, Jian Li, Yu-Qing Wu, Ke-Hao Pan, Bin Xu, Ya-Li Wang, Ming Chen

Affiliations

  1. Department of Urology, Binhai People's Hospital, Yancheng, China.
  2. Department of Nosocomial Infection, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
  3. Department of Urology, Jinhu People's Hospital, Jinhu, China.
  4. Zhongda Hospital of Southeast University, Southeast University, Lishui District People's Hospital, Nanjing, China.

PMID: 33850752 PMCID: PMC8039616 DOI: 10.21037/tau-20-1262

Abstract

BACKGROUND: Kidney cancer is the most common malignant tumor of the kidney in adults. However, in terms of the treatment for pT3a renal cell carcinoma (RCC), whether partial nephrectomy (PN) can be selected is still controversial. This study was conducted to compare the efficacy of PN and radical nephrectomy (RN) in treatment for patients with pT3a RCC.

METHODS: The relative English databases including PubMed and EMBASE were searched for studies comparing PN and RN for pT3a RCC between 2010 and 2020. Stata 13.0 software was used to compare the cancer-specific survival (CSS), overall survival (OS), cancer-specific mortality (CSM), relapse-free survival (RFS), complications and positive surgical margin.

RESULTS: Nine articles were included with a total of 3,391 patients, of whom 2,113 received RN and 1,278 received PN. The results showed that there is no statistical difference in CSS, OS, CSM, RFS, complications and positive surgical margin between RN and PN. No heterogeneity was shown in study.

CONCLUSIONS: There were no differences in the CSS, OS, CSM, RFS, complications and positive surgical margin of the patients in RN and PN group. For pT3a RCC, RN did not provide a better survival benefit compared to PN. Considering PN can suppress the progression of tumor and reduce the risk of postoperative chronic renal insufficiency, we found PN is a good choice for pT3a RCC. However, further large-sample, studies are still needed in future.

2021 Translational Andrology and Urology. All rights reserved.

Keywords: Radical nephrectomy (RN); meta-analysis; pT3a renal cell carcinoma (pT3a RCC); partial nephrectomy (PN); survival

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1262). The authors have no conflicts of interest to declare.

References

  1. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  2. Int J Urol. 2014 Apr;21(4):352-7 - PubMed
  3. J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801 - PubMed
  4. Int J Urol. 2020 Oct;27(10):906-913 - PubMed
  5. Urology. 2011 May;77(5):1142-6 - PubMed
  6. Urol Clin North Am. 2008 Nov;35(4):645-55; vii - PubMed
  7. Urology. 2014 Sep;84(3):602-8 - PubMed
  8. J Endourol. 2017 Jul;31(7):645-650 - PubMed
  9. J Urol. 2017 Sep;198(3):520-529 - PubMed
  10. J Urol. 1998 Apr;159(4):1163-7 - PubMed
  11. J Urol. 2012 Jul;188(1):51-7 - PubMed
  12. J Clin Oncol. 2017 Feb 20;35(6):668-680 - PubMed
  13. J Urol. 2004 Jul;172(1):58-62 - PubMed
  14. J Laparoendosc Adv Surg Tech A. 2019 Feb;29(2):233-239 - PubMed
  15. PLoS One. 2016 Nov 18;11(11):e0166183 - PubMed
  16. PLoS One. 2016 Feb 18;11(2):e0149420 - PubMed
  17. Eur Urol. 2011 Apr;59(4):543-52 - PubMed
  18. Urology. 2020 Apr;138:60-68 - PubMed
  19. CA Cancer J Clin. 2016 Jul;66(4):271-89 - PubMed
  20. Cureus. 2019 Sep 27;11(9):e5781 - PubMed
  21. Eur Urol. 2013 Aug;64(2):277-91 - PubMed
  22. BMC Urol. 2014 Dec 17;14:101 - PubMed
  23. Clin Genitourin Cancer. 2020 Dec;18(6):e723-e729 - PubMed
  24. BJU Int. 2012 Sep;110(6):884-90 - PubMed
  25. Urology. 2014 Apr;83(4):812-6 - PubMed
  26. Urology. 2012 Aug;80(2):347-53 - PubMed
  27. J Endourol. 2017 Feb;31(2):153-157 - PubMed
  28. Eur Urol. 2019 May;75(5):799-810 - PubMed
  29. BJU Int. 2014 Dec;114(6):903-9 - PubMed
  30. Eur Urol. 2001 Jun;39(6):669-74; discussion 675 - PubMed
  31. J Urol. 2012 Jun;187(6):2000-4 - PubMed

Publication Types